ProfileGDS5678 / 1416442_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 86% 87% 85% 86% 87% 87% 87% 86% 88% 89% 86% 87% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6379787
GSM967853U87-EV human glioblastoma xenograft - Control 26.6431786
GSM967854U87-EV human glioblastoma xenograft - Control 36.6609387
GSM967855U87-EV human glioblastoma xenograft - Control 46.4827785
GSM967856U87-EV human glioblastoma xenograft - Control 56.5233686
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4589687
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.5521887
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.6220587
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5063986
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8891388
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9274289
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.6320286
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.6788587
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7978488